Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc has demonstrated a robust financial performance, with Q3 FY25 revenue reaching $6.8 million, representing a 76% year-over-year increase, primarily fueled by contributions from the newly integrated SCN model. The substantial surge in service revenue, which more than doubled to $4.6 million, indicates effective market penetration and enhanced demand for sleep testing and treatment centers. Furthermore, the company’s ongoing expansion efforts and positive clinical outcomes from its non-invasive treatment protocols suggest a promising trajectory for future revenue growth.

Bears say

Vivos Therapeutics Inc. has reported a year-over-year revenue decline of 9% for the first half of 2025, largely attributed to its transition towards new sleep center operations, resulting in decreased quarterly revenues and lower gross margins of 55% due to discounting and shifts in service mix. Despite a rebound in revenues in the second quarter of 2025, the overall financial health of the company remains precarious with persistent operating losses, negative cash flow, and a significant accumulated deficit. Additionally, the company faces numerous risks, including challenges in achieving projected sales growth, securing necessary capital, attracting new customers, and the ongoing uncertainty regarding profitability and sustainable growth.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.